N/A N=64 TRE in Type 2 Diabetes (See Food Study 3)
Type2Diabetes
Primary: Change in Glycemic Measures- HbA1c (12w) — -0.22; -0.25 percentage of glycated hemoglobin
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=737 Determining the Preliminary Efficacy of the Emergency Department Delirium Screening and Detection Program
Delirium
Primary: Proportion of Positive Delirium Screens Among Those With Delirium — 0; 10; 0; 1 Participants
N/A N=38 Digital Youth-Nominated Support Team (YST) Program
Suicide
Primary: System Usability Scale (SUS) Score - Youth Participants — 68.3 score on a scale
N/A N=562 Indigenous Supported Agriculture "Go Healthy"
Diet, Healthy · Blood Pressure · Overweight or Obesity
Primary: Change in Diet From Baseline — 4.1; 0.4 Score
Phase 1 N=17 Evaluation of the Potential Impact of a High-fat Meal on the Pharmacokinetics of CRS3123 in Healthy Adult Participants
Food Effect in Healthy Participants
Primary: Assessment of Food Effect Based on CRS3123 PK Parameters AUC0-t, AUC0-inf, and Cmax — 129.9; 123.2; 64.9 Ratio
N/A N=12 Study of Long-Term Safety and Efficacy on Gene Therapy in Glycogen Storage Disease Type Ia
Glycogen Storage Disease Type IA · Von Gierke's Disease (GSD Type Ia)
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs and Discontinuations Due to TEAEs — 3; 3; 3; 3 Participants
N/A N=55 Feasibility Trial of a Single Session of Crisis Response Planning for Youth at High Risk for Suicide
Suicide Prevention
Primary: Number of Participants With Self-reported Use of the Treatment Plan in the Crisis Response Planning (CRP) Treatment Arms — 14; 8 Participants — p=.014
N/A N=8 Noninvasive Spinal Stimulation in Stroke
Stroke
Primary: Change in Step-length Symmetry Using Symmetry Index — 72.2; 75.8; 92.2; 76.0 Symmetry Index
N/A N=71 Effectiveness of a Pender's Health Promotion Model-Based Diabetes Self-Management Program in Gestational Diabetes: A Clinical Trial
Self-Efficacy for Decision Making · Apgar Score · Behavior Change
Primary: Health Belief Model Scale for Diabetes Patients — 3.45; 3.42 Score — p=0.015
Phase 3 N=445 Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma
Follicular Lymphoma
Primary: Progression-Free Survival (PFS) as Assessed by Investigator — 42.02; 32.76 months — p=0.0231
Phase 2 N=129 Treatment of Patients With Diffuse Large B Cell Lymphoma Who Are Not Suitable for Anthracycline Containing Chemotherapy
Diffuse Large B Cell Lymphoma
Primary: Progression Free Survival — 49.2; 46.9 percentage
N/A N=18 Hypofractionated Adjuvant Radiotherapy for Resected Head and Neck Cancers
Resectable Head and Neck Squamous Cell Carcinoma
Primary: Maximum-tolerated Radiation Dose — 32.5 Gy
Phase 2 N=220 Dose-Ranging Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine
Pneumococcal Vaccines
Primary: Solicited Local Adverse Events (AEs) — 0; 0; 0; 0 events
N/A N=27 Functionality of the Pulse Oximeter and Accelerometer Portions of a Novel Wearable Device
Hypoxic Events
Primary: Mean Absolute Error of Dove Device Compared to FDA Approved SpO2 Sensor — 0.45 percentage points
Phase 4 N=123 Anhedonia, Development, and Emotions: Phenotyping and Therapeutics
Depression · Anhedonia
Primary: Montgomery-Asberg Depression Rating Scale (MADRS) Score — 28.9; 24.9; 21.4; 20.7 score on a scale — p=<0.001